Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 95 entries
Sorted by: Best Match Show Resources per page
Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, Khandekar MJ, Balazs AB, Iafrate JA, Gainor JF, Willers H.
PMID: 34838892
Radiother Oncol. 2021 Nov 25;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25.

The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody...

Cite
Bowes CL, Naranbhai V, St Denis KJ, et al. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2021;166:88-91doi: 10.1016/j.radonc.2021.11.012.
Bowes, C. L., Naranbhai, V., St Denis, K. J., Lam, E. C., Bertaux, B., Keane, F. K., Khandekar, M. J., Balazs, A. B., Iafrate, J. A., Gainor, J. F., & Willers, H. (2021). Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16688-91. https://doi.org/10.1016/j.radonc.2021.11.012
Bowes, Cynthia L, et al. "Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 88-91. doi: https://doi.org/10.1016/j.radonc.2021.11.012
Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, Khandekar MJ, Balazs AB, Iafrate JA, Gainor JF, Willers H. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2021 Nov 25;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25. PMID: 34838892; PMCID: PMC8613981.
Copy Download .nbib Format: NLM
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, Hurvitz SA, Moy B, Kim SB, Gradishar WJ, Queiroz GS, Cronemberger E, Wallweber GJ, Bebchuk J, Keyvanjah K, Lalani AS, Bryce R, Vivancos A, Eli LD, Delaloge S.
PMID: 34380637
Clin Cancer Res. 2021 Nov 01;27(21):5818-5827. doi: 10.1158/1078-0432.CCR-21-1584. Epub 2021 Aug 11.

No abstract available.

Cite
Saura C, Matito J, Oliveira M, et al. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res. 2021;27(21):5818-5827doi: 10.1158/1078-0432.CCR-21-1584.
Saura, C., Matito, J., Oliveira, M., Wildiers, H., Brufksy, A. M., Waters, S. H., Hurvitz, S. A., Moy, B., Kim, S. B., Gradishar, W. J., Queiroz, G. S., Cronemberger, E., Wallweber, G. J., Bebchuk, J., Keyvanjah, K., Lalani, A. S., Bryce, R., Vivancos, A., Eli, L. D., & Delaloge, S. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(21), 5818-5827. https://doi.org/10.1158/1078-0432.CCR-21-1584
Saura, Cristina, et al. "Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,21 (2021): 5818-5827. doi: https://doi.org/10.1158/1078-0432.CCR-21-1584
Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, Hurvitz SA, Moy B, Kim SB, Gradishar WJ, Queiroz GS, Cronemberger E, Wallweber GJ, Bebchuk J, Keyvanjah K, Lalani AS, Bryce R, Vivancos A, Eli LD, Delaloge S. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res. 2021 Nov 01;27(21):5818-5827. doi: 10.1158/1078-0432.CCR-21-1584. Epub 2021 Aug 11. PMID: 34380637.
Copy Download .nbib Format: NLM
HCN4 current during human sinoatrial node-like action potentials.

Progress in biophysics and molecular biology

Hoekstra M, van Ginneken ACG, Wilders R, Verkerk AO.
PMID: 34153331
Prog Biophys Mol Biol. 2021 Nov;166:105-118. doi: 10.1016/j.pbiomolbio.2021.05.006. Epub 2021 Jun 18.

BACKGROUND: Despite the many studies carried out over the past 40 years, the contribution of the HCN4 encoded hyperpolarization-activated 'funny' current (IOBJECTIVE: To study the contribution of IMETHODS: HCN4 channels were expressed in human cardiac myocyte progenitor cells (CMPCs)...

Cite
Hoekstra M, van Ginneken ACG, Wilders R, et al. HCN4 current during human sinoatrial node-like action potentials. Prog Biophys Mol Biol. 2021;166:105-118doi: 10.1016/j.pbiomolbio.2021.05.006.
Hoekstra, M., van Ginneken, A. C. G., Wilders, R., & Verkerk, A. O. (2021). HCN4 current during human sinoatrial node-like action potentials. Progress in biophysics and molecular biology, 166105-118. https://doi.org/10.1016/j.pbiomolbio.2021.05.006
Hoekstra, Maaike, et al. "HCN4 current during human sinoatrial node-like action potentials." Progress in biophysics and molecular biology vol. 166 (2021): 105-118. doi: https://doi.org/10.1016/j.pbiomolbio.2021.05.006
Hoekstra M, van Ginneken ACG, Wilders R, Verkerk AO. HCN4 current during human sinoatrial node-like action potentials. Prog Biophys Mol Biol. 2021 Nov;166:105-118. doi: 10.1016/j.pbiomolbio.2021.05.006. Epub 2021 Jun 18. PMID: 34153331.
Copy Download .nbib Format: NLM
Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Slembrouck L, Vanden Bempt I, Wildiers H, Smeets A, Van Rompuy AS, Van Ongeval C, Jongen L, Weltens C, Punie K, Hoste G, Van Nieuwenhuysen E, Han S, Nevelsteen I, Neven P, Floris G.
PMID: 33558657
Mod Pathol. 2021 Jul;34(7):1297-1309. doi: 10.1038/s41379-021-00743-8. Epub 2021 Feb 08.

Multigene signatures (MGS) are used to guide adjuvant chemotherapy (aCT) decisions in patients diagnosed with estrogen receptor (ER)-positive HER2-negative early breast cancer. We used results from three MGS (Oncotype DX® (ODX), MammaPrint® (MP) or Prosigna®) and assessed the concordance...

Cite
Slembrouck L, Vanden Bempt I, Wildiers H, et al. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer. Mod Pathol. 2021;34(7):1297-1309doi: 10.1038/s41379-021-00743-8.
Slembrouck, L., Vanden Bempt, I., Wildiers, H., Smeets, A., Van Rompuy, A. S., Van Ongeval, C., Jongen, L., Weltens, C., Punie, K., Hoste, G., Van Nieuwenhuysen, E., Han, S., Nevelsteen, I., Neven, P., & Floris, G. (2021). Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 34(7), 1297-1309. https://doi.org/10.1038/s41379-021-00743-8
Slembrouck, Laurence, et al. "Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 34,7 (2021): 1297-1309. doi: https://doi.org/10.1038/s41379-021-00743-8
Slembrouck L, Vanden Bempt I, Wildiers H, Smeets A, Van Rompuy AS, Van Ongeval C, Jongen L, Weltens C, Punie K, Hoste G, Van Nieuwenhuysen E, Han S, Nevelsteen I, Neven P, Floris G. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer. Mod Pathol. 2021 Jul;34(7):1297-1309. doi: 10.1038/s41379-021-00743-8. Epub 2021 Feb 08. PMID: 33558657.
Copy Download .nbib Format: NLM
Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1.

Frontiers in physiology

Meijer van Putten RM, Mengarelli I, Guan K, Zegers JG, van Ginneken AC, Verkerk AO, Wilders R.
PMID: 25691870
Front Physiol. 2015 Feb 03;6:7. doi: 10.3389/fphys.2015.00007. eCollection 2015.

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) are widely used in studying basic mechanisms of cardiac arrhythmias that are caused by ion channelopathies. Unfortunately, the action potential profile of hiPSC-CMs-and consequently the profile of individual membrane currents active...

Cite
Meijer van Putten RM, Mengarelli I, Guan K, et al. Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1. Front Physiol. 2015;6:7doi: 10.3389/fphys.2015.00007.
Meijer van Putten, R. M., Mengarelli, I., Guan, K., Zegers, J. G., van Ginneken, A. C., Verkerk, A. O., & Wilders, R. (2015). Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1. Frontiers in physiology, 67. https://doi.org/10.3389/fphys.2015.00007
Meijer van Putten, Rosalie M E, et al. "Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1." Frontiers in physiology vol. 6 (2015): 7. doi: https://doi.org/10.3389/fphys.2015.00007
Meijer van Putten RM, Mengarelli I, Guan K, Zegers JG, van Ginneken AC, Verkerk AO, Wilders R. Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1. Front Physiol. 2015 Feb 03;6:7. doi: 10.3389/fphys.2015.00007. eCollection 2015. PMID: 25691870; PMCID: PMC4315032.
Copy Download .nbib Format: NLM
Isotope dilution - high efficiency nebulization-ICP-MS: The coupling of accuracy and sensitivity.

Analytical and bioanalytical chemistry

Wildner H, Wünsch G.
PMID: 15048392
Anal Bioanal Chem. 1996 Mar;354(7):807-10. doi: 10.1007/s0021663540807.

If sample pretreatment, nebulization and method of calibration are suitably adapted to each other the performance of inductively coupled plasma - mass spectrometry ICP-MS can be greatly increased. High accuracy is obtained by high precision and low bias. For...

Cite
Wildner H, Wünsch G. Isotope dilution - high efficiency nebulization-ICP-MS: The coupling of accuracy and sensitivity. Anal Bioanal Chem. 1996;354(7):807-10doi: 10.1007/s0021663540807.
Wildner, H., & Wünsch, G. (1996). Isotope dilution - high efficiency nebulization-ICP-MS: The coupling of accuracy and sensitivity. Analytical and bioanalytical chemistry, 354(7), 807-10. https://doi.org/10.1007/s0021663540807
Wildner, H, and Wünsch, G. "Isotope dilution - high efficiency nebulization-ICP-MS: The coupling of accuracy and sensitivity." Analytical and bioanalytical chemistry vol. 354,7 (1996): 807-10. doi: https://doi.org/10.1007/s0021663540807
Wildner H, Wünsch G. Isotope dilution - high efficiency nebulization-ICP-MS: The coupling of accuracy and sensitivity. Anal Bioanal Chem. 1996 Mar;354(7):807-10. doi: 10.1007/s0021663540807. PMID: 15048392.
Copy Download .nbib Format: NLM
Author Correction: Circuit dissection of the role of somatostatin in itch and pain.

Nature neuroscience

Huang J, Polgár E, Solinski HJ, Mishra SK, Tseng PY, Iwagaki N, Boyle KA, Dickie AC, Kriegbaum MC, Wildner H, Zeilhofer HU, Watanabe M, Riddell JS, Todd AJ, Hoon MA.
PMID: 29674654
Nat Neurosci. 2018 Jun;21(6):894. doi: 10.1038/s41593-018-0149-6.

In the version of this article initially published online, the labels were switched for the right-hand pair of bars in Fig. 4e. The left one of the two should be Chloroquine + veh, the right one Chloroquine + CNO....

Cite
Huang J, Polgár E, Solinski HJ, et al. Author Correction: Circuit dissection of the role of somatostatin in itch and pain. Nat Neurosci. 2018;21(6):894doi: 10.1038/s41593-018-0149-6.
Huang, J., Polgár, E., Solinski, H. J., Mishra, S. K., Tseng, P. Y., Iwagaki, N., Boyle, K. A., Dickie, A. C., Kriegbaum, M. C., Wildner, H., Zeilhofer, H. U., Watanabe, M., Riddell, J. S., Todd, A. J., & Hoon, M. A. (2018). Author Correction: Circuit dissection of the role of somatostatin in itch and pain. Nature neuroscience, 21(6), 894. https://doi.org/10.1038/s41593-018-0149-6
Huang, Jing, et al. "Author Correction: Circuit dissection of the role of somatostatin in itch and pain." Nature neuroscience vol. 21,6 (2018): 894. doi: https://doi.org/10.1038/s41593-018-0149-6
Huang J, Polgár E, Solinski HJ, Mishra SK, Tseng PY, Iwagaki N, Boyle KA, Dickie AC, Kriegbaum MC, Wildner H, Zeilhofer HU, Watanabe M, Riddell JS, Todd AJ, Hoon MA. Author Correction: Circuit dissection of the role of somatostatin in itch and pain. Nat Neurosci. 2018 Jun;21(6):894. doi: 10.1038/s41593-018-0149-6. PMID: 29674654.
Copy Download .nbib Format: NLM
Ultrarapid Delayed Rectifier K.

Frontiers in cell and developmental biology

Hilderink S, Devalla HD, Bosch L, Wilders R, Verkerk AO.
PMID: 32850774
Front Cell Dev Biol. 2020 Jul 28;8:536. doi: 10.3389/fcell.2020.00536. eCollection 2020.

Atrial fibrillation (AF) is the most common cardiac arrhythmia. About 5-15% of AF patients have a mutation in a cardiac gene, including mutations in

Cite
Hilderink S, Devalla HD, Bosch L, et al. Ultrarapid Delayed Rectifier K. Front Cell Dev Biol. 2020;8:536doi: 10.3389/fcell.2020.00536.
Hilderink, S., Devalla, H. D., Bosch, L., Wilders, R., & Verkerk, A. O. (2020). Ultrarapid Delayed Rectifier K. Frontiers in cell and developmental biology, 8536. https://doi.org/10.3389/fcell.2020.00536
Hilderink, Sarah, et al. "Ultrarapid Delayed Rectifier K." Frontiers in cell and developmental biology vol. 8 (2020): 536. doi: https://doi.org/10.3389/fcell.2020.00536
Hilderink S, Devalla HD, Bosch L, Wilders R, Verkerk AO. Ultrarapid Delayed Rectifier K. Front Cell Dev Biol. 2020 Jul 28;8:536. doi: 10.3389/fcell.2020.00536. eCollection 2020. PMID: 32850774; PMCID: PMC7399090.
Copy Download .nbib Format: NLM
Reply to L.K. Mell et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Ballman KV, Mauer M, Wedding U, Mohile SG, Muss H, Extermann M, Luciani A, Cohen HJ, Hurria A, Lichtman SM, Curigliano G, Wildiers H.
PMID: 24550420
J Clin Oncol. 2014 Apr 01;32(10):1090-1. doi: 10.1200/JCO.2013.54.5236. Epub 2014 Feb 18.

No abstract available.

Cite
Ballman KV, Mauer M, Wedding U, et al. Reply to L.K. Mell et al. J Clin Oncol. 2014;32(10):1090-1doi: 10.1200/JCO.2013.54.5236.
Ballman, K. V., Mauer, M., Wedding, U., Mohile, S. G., Muss, H., Extermann, M., Luciani, A., Cohen, H. J., Hurria, A., Lichtman, S. M., Curigliano, G., & Wildiers, H. (2014). Reply to L.K. Mell et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(10), 1090-1. https://doi.org/10.1200/JCO.2013.54.5236
Ballman, Karla V, et al. "Reply to L.K. Mell et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 32,10 (2014): 1090-1. doi: https://doi.org/10.1200/JCO.2013.54.5236
Ballman KV, Mauer M, Wedding U, Mohile SG, Muss H, Extermann M, Luciani A, Cohen HJ, Hurria A, Lichtman SM, Curigliano G, Wildiers H. Reply to L.K. Mell et al. J Clin Oncol. 2014 Apr 01;32(10):1090-1. doi: 10.1200/JCO.2013.54.5236. Epub 2014 Feb 18. PMID: 24550420.
Copy Download .nbib Format: NLM
Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer.

SpringerPlus

Smeets A, Ryckx A, Belmans A, Wildiers H, Neven P, Floris G, Schöffski P, Christiaens MR.
PMID: 24083118
Springerplus. 2013 Sep 23;2:480. doi: 10.1186/2193-1801-2-480. eCollection 2013.

SYNOPSIS: The significance of nodal metastasis in breast cancer is under discussion. We investigated the impact of variables of tumor chronology and tumor biology on the presence of lymph node metastases.PURPOSE: Lymph node involvement is the main prognostic factor...

Cite
Smeets A, Ryckx A, Belmans A, et al. Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer. Springerplus. 2013;2:480doi: 10.1186/2193-1801-2-480.
Smeets, A., Ryckx, A., Belmans, A., Wildiers, H., Neven, P., Floris, G., Schöffski, P., & Christiaens, M. R. (2013). Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer. SpringerPlus, 2480. https://doi.org/10.1186/2193-1801-2-480
Smeets, Ann, et al. "Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer." SpringerPlus vol. 2 (2013): 480. doi: https://doi.org/10.1186/2193-1801-2-480
Smeets A, Ryckx A, Belmans A, Wildiers H, Neven P, Floris G, Schöffski P, Christiaens MR. Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer. Springerplus. 2013 Sep 23;2:480. doi: 10.1186/2193-1801-2-480. eCollection 2013. PMID: 24083118; PMCID: PMC3786086.
Copy Download .nbib Format: NLM
Cardiac ion channelopathies and the sudden infant death syndrome.

ISRN cardiology

Wilders R.
PMID: 23304551
ISRN Cardiol. 2012;2012:846171. doi: 10.5402/2012/846171. Epub 2012 Dec 05.

The sudden infant death syndrome (SIDS) causes the sudden death of an apparently healthy infant, which remains unexplained despite a thorough investigation, including the performance of a complete autopsy. The triple risk model for the pathogenesis of SIDS points...

Cite
Wilders R. Cardiac ion channelopathies and the sudden infant death syndrome. ISRN Cardiol. 2012;2012:846171doi: 10.5402/2012/846171.
Wilders, R. (2012). Cardiac ion channelopathies and the sudden infant death syndrome. ISRN cardiology, 2012846171. https://doi.org/10.5402/2012/846171
Wilders, Ronald. "Cardiac ion channelopathies and the sudden infant death syndrome." ISRN cardiology vol. 2012 (2012): 846171. doi: https://doi.org/10.5402/2012/846171
Wilders R. Cardiac ion channelopathies and the sudden infant death syndrome. ISRN Cardiol. 2012;2012:846171. doi: 10.5402/2012/846171. Epub 2012 Dec 05. PMID: 23304551; PMCID: PMC3529486.
Copy Download .nbib Format: NLM
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Sarcoma

Huygh G, Clement PM, Dumez H, Schöffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT.
PMID: 17496996
Sarcoma. 2006;2006:56282. doi: 10.1155/SRCM/2006/56282. Epub 2006 Dec 31.

Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900-1500...

Cite
Huygh G, Clement PM, Dumez H, et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006;2006:56282doi: 10.1155/SRCM/2006/56282.
Huygh, G., Clement, P. M., Dumez, H., Schöffski, P., Wildiers, H., Selleslach, J., Jimeno, J. M., Wever, I. D., Sciot, R., Duck, L., & Van Oosterom, A. T. (2006). Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma, 200656282. https://doi.org/10.1155/SRCM/2006/56282
Huygh, G, et al. "Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients." Sarcoma vol. 2006 (2006): 56282. doi: https://doi.org/10.1155/SRCM/2006/56282
Huygh G, Clement PM, Dumez H, Schöffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006;2006:56282. doi: 10.1155/SRCM/2006/56282. Epub 2006 Dec 31. PMID: 17496996; PMCID: PMC1820623.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 95 entries